A phase II trial of HER-Vaxx plus chemotherapy demonstrated a 40% survival benefit compared to chemotherapy alone in patients with HER2-overexpressing gastric cancer.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.